A Phase 1 Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Latest Information Update: 26 Jun 2025
At a glance
- Drugs Felmetatug vedotin (Primary)
- Indications Adenocarcinoma; Adenoid cystic carcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Seagen
Most Recent Events
- 19 Jun 2025 Status changed from active, no longer recruiting to discontinued.
- 20 Apr 2025 Planned End Date changed from 30 Nov 2027 to 3 Dec 2025.
- 20 Apr 2025 Planned primary completion date changed from 30 Nov 2027 to 3 Dec 2025.